Mutations and altered expression of p16INK4 in human cancer.

PubWeight™: 2.64‹?› | Rank: Top 1%

🔗 View Article (PMC 45163)

Published in Proc Natl Acad Sci U S A on November 08, 1994

Authors

A Okamoto1, D J Demetrick, E A Spillare, K Hagiwara, S P Hussain, W P Bennett, K Forrester, B Gerwin, M Serrano, D H Beach

Author Affiliations

1: Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Articles citing this

The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08

Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67

Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol (1995) 3.19

Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A (1995) 3.08

Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A (1996) 2.30

Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol (1995) 1.85

HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J (1996) 1.69

Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol (1999) 1.51

The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46

Stimulation of cyclin-dependent kinase activity and G1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein. J Virol (1998) 1.43

p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol (1998) 1.39

Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31

Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer (1998) 1.28

A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol (2000) 1.26

Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol (2016) 1.20

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer (1996) 1.19

Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol (2005) 1.15

Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. Am J Pathol (1995) 1.13

Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell (1996) 1.12

Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med (1998) 1.06

Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol (1996) 1.06

Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol (1998) 1.04

Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol (2003) 1.04

Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer (1999) 1.03

Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol (1998) 1.00

p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. Diagn Pathol (2009) 1.00

Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00

A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish-swordtail hybrids. Proc Natl Acad Sci U S A (1996) 0.99

Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2. World J Gastroenterol (2001) 0.98

Methylation status of p16 gene in colorectal carcinoma and normal colonic mucosa. World J Gastroenterol (1999) 0.97

Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression. Mol Cell Biol (2006) 0.97

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer (1995) 0.96

v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity. Mol Cell Biol (2000) 0.96

Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet (1996) 0.96

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol (1995) 0.95

Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem (2004) 0.95

Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol (1997) 0.93

Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci U S A (1994) 0.92

Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deficient cells. EMBO J (2014) 0.90

Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer (1995) 0.90

High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer (1999) 0.90

Real-time in vivo imaging of p16gene expression: a new approach to study senescence stress signaling in living animals. Cell Div (2010) 0.89

Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle (2008) 0.88

What we could do now: molecular pathology of colorectal cancer. Mol Pathol (2001) 0.88

Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br J Cancer (1997) 0.87

The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer? J Clin Invest (2010) 0.87

Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol (2006) 0.87

Failure of cell cleavage induces senescence in tetraploid primary cells. Mol Biol Cell (2014) 0.86

WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia (2005) 0.86

P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol (2011) 0.84

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. Br J Cancer (1996) 0.84

p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma. Mol Pathol (1998) 0.84

Identification of cyclin D3 as a direct target of E2A using DamID. Mol Cell Biol (2004) 0.84

Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma. J Clin Pathol (2006) 0.83

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer (1999) 0.81

Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer (1999) 0.81

Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies. PLoS One (2015) 0.81

Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol (2006) 0.81

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med (2016) 0.80

The EGF receptor ligand amphiregulin controls cell division via FoxM1. Oncogene (2015) 0.80

Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer (1996) 0.79

The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding. PLoS One (2013) 0.79

Genetic prognostic markers in colorectal cancer. Mol Pathol (1997) 0.79

Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. Radiat Res (2016) 0.79

Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63. Chromosome Res (2008) 0.79

Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36. Cancer Cell Int (2001) 0.79

Contributions of differential p53 expression in the spontaneous immortalization of a chicken embryo fibroblast cell line. BMC Cell Biol (2006) 0.79

p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol (2003) 0.79

High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer (1996) 0.79

Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer (1996) 0.79

Colorectal cancer cells Caco-2 and HCT116 resist epigenetic effects of isothiocyanates and selenium in vitro. Eur J Nutr (2012) 0.78

Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma. Sci Rep (2015) 0.78

Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress. J Biol Chem (2013) 0.78

UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53. Proc Natl Acad Sci U S A (2001) 0.78

Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer (1997) 0.77

Antagonizing pathways leading to differential dynamics in colon carcinogenesis in Shugoshin1 (Sgo1)-haploinsufficient chromosome instability model. Mol Carcinog (2015) 0.77

Long-term quiescent fibroblast cells transit into senescence. PLoS One (2014) 0.77

The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells. Korean J Intern Med (1999) 0.77

Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies. PLoS One (2016) 0.75

Allele-specific locus binding and genome editing by CRISPR at the p16INK4a locus. Sci Rep (2016) 0.75

Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway. Oncotarget (2017) 0.75

Articles cited by this

WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20

p53 mutations in human cancers. Science (1991) 31.96

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29

Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (1992) 10.28

G1 events and regulation of cell proliferation. Science (1989) 9.73

Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell (1992) 9.19

Mammalian G1 cyclins. Cell (1993) 9.04

p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52

Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev (1993) 7.41

Clinical implications of the p53 tumor-suppressor gene. N Engl J Med (1993) 7.29

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19

p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05

A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell (1992) 6.32

Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res (1994) 6.16

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06

Tumor suppressor genes. Science (1991) 5.72

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell (1992) 5.51

Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31

Gain of function mutations in p53. Nat Genet (1993) 4.19

Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell (1992) 4.05

A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol (1993) 3.38

Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene (1993) 2.99

Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A (1994) 2.87

Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol (1993) 2.37

Braking the cycle. Cell (1993) 2.34

Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science (1990) 2.28

Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16

How sensitive is PCR-SSCP? Hum Mutat (1993) 2.13

Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A (1994) 2.09

Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A (1993) 1.84

Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med (1990) 1.82

Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res (1994) 1.80

Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene (1994) 1.77

A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. Mol Cell Biol (1993) 1.70

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

Allelotype of human bladder cancer. Cancer Res (1994) 1.38

Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res (1991) 1.25

Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res (1994) 1.21

Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res (1993) 1.17

Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res (1993) 1.08

Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet (1993) 1.01

Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis (1990) 1.00

Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. Cancer Res (1993) 0.91

Inducible growth arrest: new mechanistic insights. Proc Natl Acad Sci U S A (1994) 0.88

Articles by these authors

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60

Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (1987) 5.46

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46

The fission yeast cdc2/cdc13/suc1 protein kinase: regulation of catalytic activity and nuclear localization. Cell (1989) 4.95

p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89

Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 4.37

A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med (1999) 4.15

Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80

Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76

p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol (2000) 3.15

Twist is a potential oncogene that inhibits apoptosis. Genes Dev (1999) 3.14

A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10

Rearrangements of the transposable mating-type cassettes of fission yeast. EMBO J (1984) 2.91

p53 mutations in human immortalized epithelial cell lines. Carcinogenesis (1993) 2.82

Genes required for initiation and resolution steps of mating-type switching in fission yeast. Proc Natl Acad Sci U S A (1984) 2.71

[Yield of laboratory tests in the detection of excessive drinkers in the work place]. Med Clin (Barc) (1993) 2.64

Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res (2001) 2.37

Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res (2000) 2.31

Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst (2000) 2.27

Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25

Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol (2000) 2.17

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol (2012) 2.17

Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res (1998) 2.15

Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst (1999) 2.10

p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res (1991) 2.09

p34cdc2-mediated phosphorylation at T124 inhibits nuclear import of SV-40 T antigen proteins. J Cell Biol (1991) 2.08

Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene (1995) 2.05

DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00

Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene (1999) 2.00

Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A (1993) 1.95

Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem (2000) 1.88

The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. J Biol Chem (1999) 1.84

Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene (2009) 1.78

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78

Mutations associated with familial melanoma impair p16INK4 function. Nat Genet (1995) 1.69

Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68

Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene (2010) 1.67

Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res (1995) 1.64

The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63

Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol (1999) 1.62

Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature (1998) 1.61

p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet (1994) 1.56

p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med (1998) 1.55

Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer (2006) 1.53

Induction of senescence by oncogenic Ras. Methods Enzymol (2001) 1.52

Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood (2001) 1.49

The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J (1999) 1.48

[Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi (1987) 1.48

Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 1.45

Evolutionary relationships among proteins in the phytohemagglutinin-arcelin-alpha-amylase inhibitor family of the common bean and its relatives. Plant Mol Biol (1994) 1.44

In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother (2001) 1.44

The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med (2000) 1.43

Lung cancer after Hodgkin's disease. J Natl Cancer Inst (1995) 1.42

[Diffuse mediastinal lipomatosis and exogenous obesity]. Rev Clin Esp (1993) 1.39

Fahr's syndrome presenting with pure and progressive presenile dementia. Neurol Sci (2005) 1.39

Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood (1992) 1.39

Risky immortalization by telomerase. Nature (2000) 1.38

[Non-Hodgkin's lymphomas associated with the acquired immunodeficiency syndrome. A multicenter clinical study of 77 cases]. Med Clin (Barc) (1995) 1.38

Equine Borna disease in Japan. Vet Rec (2001) 1.38

Functional interaction of p53 and BLM DNA helicase in apoptosis. J Biol Chem (2001) 1.37

Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol (1986) 1.37

Sterols of Leishmania species. Implications for biosynthesis. Mol Biochem Parasitol (1984) 1.37

Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene (2006) 1.32

Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res (1990) 1.31

Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res (1996) 1.29

Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci U S A (1989) 1.26

Cytopathogenic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro. Infect Immun (2000) 1.25

Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res (1995) 1.23

The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol (1989) 1.23

p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res (2001) 1.23

Interaction of the bacteriophage phi 29 protein p6 with double-stranded DNA. Proc Natl Acad Sci U S A (1988) 1.21

p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res (1992) 1.20

Evidence for the presence of "metabolic sterols" in Pneumocystis: identification and initial characterization of Pneumocystis carinii sterols. J Eukaryot Microbiol (1994) 1.20

A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature (1987) 1.20

Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 1.20

Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res (1991) 1.20

Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Invest Ophthalmol Vis Sci (1999) 1.18

Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol (1995) 1.17

Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes. Mol Biochem Parasitol (1985) 1.16

Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J (1997) 1.16

A minor outer capsid protein, P9, of Rice dwarf virus. Arch Virol (2003) 1.16

Lipids of Leishmania promastigotes. J Parasitol (1979) 1.15

Identification of the lipid moiety and further characterization of the novel lipophosphoglycan-like glycoconjugates of Trichomonas vaginalis and Trichomonas foetus. Arch Biochem Biophys (1994) 1.15

Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst (1995) 1.15

Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway. J Biol Chem (2001) 1.13

Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A (1998) 1.12

17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharmacol (1997) 1.10

SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ (2010) 1.10

Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer (1998) 1.10

Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene (2001) 1.10